Gilead Sciences Inc

Gilead Sciences, Inc. (GILD): Growth Outlook Supported by Analyst Updates

amefika3 months ago02 mins

Gilead Sciences Inc. (NASDAQ:BROWN) is one of Goldman Sachs’ top healthcare stocks. On March 10, Jefferies initiated coverage of Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target. The research firm has touted the company’s earnings per share growth and margin expansion prospects as part of its bullish thesis. Gilead Sciences,…

Morgan Stanley Expects Gilead Sciences (GILD) to Prosper as Biopharma Policy Uncertainties Dissipate in 2026

amefika5 months ago02 mins

Gilead Sciences Inc. (NASDAQ:BROWN) is one of the best stocks for the next decade. On Dec. 12, Morgan Stanley raised the company’s price target for Gilead to $151 from $147 with an Overweight rating on the stock. The company informed investors that the regulatory and political uncertainties currently weighing on the biopharmaceutical are expected to…